JW (Cayman) Therapeutics Co Ltd
02126
Company Profile
Business description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Contact
No. 699 Zhong Ke Road
5th Floor, Building B
Pudong New District
Shanghai
CHNT: +86 2150464201
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
281
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.40 | 40.30 | -0.47% |
| CAC 40 | 7,864.44 | 46.05 | -0.58% |
| DAX 40 | 23,999.17 | 123.23 | -0.51% |
| Dow JONES (US) | 42,019.28 | 158.84 | 0.38% |
| FTSE 100 | 8,739.26 | 47.20 | -0.54% |
| HKSE | 23,544.31 | 283.47 | -1.19% |
| NASDAQ | 19,019.87 | 147.22 | 0.78% |
| Nikkei 225 | 36,985.87 | 313.11 | -0.84% |
| NZX 50 Index | 12,662.25 | 40.85 | -0.32% |
| S&P 500 | 5,865.78 | 21.17 | 0.36% |
| S&P/ASX 200 | 8,348.70 | 38.10 | -0.45% |
| SSE Composite Index | 3,380.19 | 7.39 | -0.22% |